Abstract
Purpose: This study is to conduct systematic review of randomized controlled trial using herbal medicine ‘Bojungikgitang’ and classify the indication of Bojungikgi-tang by ICD-10. Methods:We searched RCTs reporting effect of Bojungikgitang. Literatures were searched from the electronic databases including PubMed, EMBASE, Cochrane CENTRAL, CNKI, CiNii, CINAHL, 5 Koreanmedical databases and 2 databases specialized in Korean medicine. There was no limitation of language and publication year. The risk of bias was evaluated by the ‘Risk of Bias’ tool of Cochrane group. Literatures were descriptively analyzed. The indications of Bojungikgi-tang in RCT were classified by ICD-10. Results: From the 1,883 of relevant literatures, 31 were included. 2,440 participants were involved in RCT using Bojungikgi-tang. The average administration period of Bojungikgi-tang was 56±48.45 days. In clinical trials, Bojungikgi-tang is mainly used as three indications; a tumorrelated disease, loss of appetite and fatigue, and immunerelated diseases. Especially, Bojungikgi-tang is mostly used in cancer related disease (24%). Conclusion: This study classified various indications of Bojungikgi-tang in clinical trials and identified multi target effect of Bojungikgi-tang. This review would contribute to provide useful information in the clinical use of Bojungikgitang. Contact: Somi Oh, veroni5ca@naver.com
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
